Skip to main content

Coronavirus (COVID-19) Updates: Visitation Policies (New! 11.25.20) | How We're Keeping You Safe | Latest COVID Information

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

CGIP19127 / A021602 / Aram Hezel

Research Question:
How well does cabozantinib S-malate work compared with placebo in treating patients with neuroendocrine tumors that have spread after previous treatment with everolimus?

Basic Study Information

Purpose:
This randomized phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that have spread to other places in the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.

Location: University of Rochester Medical Center
Study Reference #: CGIP19127

Lead Researcher (Principal Investigator)

Lead Researcher:  Aram Hezel

Study Contact Information

Study Coordinator: Tina Bowdish
Phone: +1 585-275-9475
Email: tina_bowdish@urmc.rochester.edu

Additional Study Details

Return to Search